October 18, 2024

Critical Pathway for rare brain tumor discovered

Critical Pathway for rare brain tumor discovered

Choroid plexus tumors mainly affect toddlers under one year of age. Scientists at the German Cancer Research Center (DKFZ) have now been able to show that a permanently activated important signaling pathway of intracellular communication is responsible for the development of these rare brain tumors.

Crystal Structure of Wnt8
© Kevinmjude/Wikipedia

Tumors of the choroid plexus develop as a result of proliferation of the specialized epithelial cells known to produce the cerebrospinal fluid. Choroid plexus tumors (CPT) are very rare, but are among the most common neoplasms of the central nervous system in infants under one year of age. It is noteworthy that they can already be detected in the third trimester of pregnancy.

CPT can be categorized into the rather benign plexus papillomas and the malignant plexus carcinomas. Choroid plexus papillomas have very good chances of healing, whereas the prognosis for choroid plexus carcinomas is unfavorable. Due to their rarity, these tumors have not been well studied. “It was known that choroid plexus tumors have extensive chromosome defects, but so far no specific cancer-driving mutations have been identified that favor the development of these tumors,” says Annarita Patrizi, a junior research group leader at the DKFZ.

Together with her research group, Patrizi has now presented the results of a comprehensive study of these tumors for the first time. The researchers first compared the gene activity in chroroid plexus tumors and healthy tissue of this brain structure. In the tumors, they found a particularly high number of deviations in components of the so-called Wnt/β-catenin signaling pathway. This important intracellular communication pathway is involved in many processes during embryonic development, for example in organ formation. In adult cells, the signaling pathway is mostly inactive, but in tumor cells it can be reactivated.

Staining of tissue samples from human CPT confirmed that Wnt is constantly activated in the cancer cells. The researchers showed that CPT cells depend on Wnt activity for their survival and growth. If Wnt activity is boosted, this is enough for choroid plexus cells to develop tumor-typical properties such as accelerated proliferation and invasive potential.

Cells in choroid plexus organoids grown in the culture dish are less differentiated when the Wnt inhibitor APC is genetically switched off, thereby enhancing the Wnt signal. They show signs of transformation into tumor cells.

“The constitutive activation of Wnt in the early developmental phases of the choroid plexus apparently leads to a loss of identity of the plexus epithelium, both in mouse and in human organoids. It is conceivable that the normal development of this brain structure depends on the correct spatio-temporal activation of Wnt. Disruptions to the temporal course can impair normal development and lead to tumorigenesis,” explains Patrizi.

Due to its important role in tissue development and homeostasis, the Wnt signaling pathway is an attractive but challenging target for precision oncology. Several clinical trials are currently underway to inhibit this pathway using various strategies. A Wnt inhibitor is currently in phase 1-2 clinical trials for solid tumors.

“We were able to show that this drug inhibits cell proliferation and impairs survival in a CPT cell line,” said Patrizi. “Further research, especially on choroid plexus organoids, should help to finally find targeted treatment options for this disease.”

Hoa Ho K, Trapp M, Guida C, Ivanova EL, De Jaime-Soguero A, Jabali A, Thomas C, Salasova A, Bernatík O, Salio C, Horschitz S, Hasselblatt M, Sassoe-Pognetto M, Čajánek L, Ishikawa H, Schroten H, Schwerk C, Acebrón SP, Angel P, Koch P, Patrizi A.: Activation of Wnt/β-catenin signaling is critical for the tumorigenesis of choroid plexus.
Neuro Oncol. 2024, DOI: 10.1093/neuonc/noae176

Original News

Our latest News

discover more
BioMed X and Servier Launch First XSeed Labs in Europe

BioMed X and Servier Launch First XSeed Labs in Europe

Heidelberg, Germany / Paris, France, July 9th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe […]

Investigating kinase activity in living cells

Investigating kinase activity in living cells

Scientists build molecular recording tool The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research in Heidelberg have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This […]

The evolution of cancer cells decoded

The evolution of cancer cells decoded

Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp